of one or both eyelids, blurred vision, change in facial
expression, difficulty swallowing, shortness of breath, impaired
speech and weakness in the arms, hands, fingers, legs or neck;
and
WHEREAS, The distinctive symptom of myasthenia gravis is
muscle weakness that worsens after periods of activity and
improves with periods of rest; and
WHEREAS, Although myasthenia gravis affects men and women
across all racial and ethnic groups, the disorder most commonly
impacts young adult women under 40 years of age or older men
over 60 years of age; and
WHEREAS, Even though myasthenia gravis can generally be
controlled, there are times during a myasthenic crisis when
emergency medical treatment is necessary and muscle weakness
requires a ventilator; and
WHEREAS, The National Institutes of Health and the National
Institute of Neurological Disorders and Stroke (NINDS) seek
greater understanding about the structure and function of the
neuromuscular junction that is impacted by myasthenia gravis;
and
WHEREAS, Findings from a recent NINDS-supported study yielded
conclusive evidence about the benefits of surgery for
individuals suffering from myasthenia gravis who do not have
thymoma; and
WHEREAS, Researchers are exploring better ways to treat
myasthenia gravis by developing new tools to better diagnose
individuals with undetectable antibodies and potential
biomarkers; therefore be it
RESOLVED, That the House of Representatives recognize the
month of June 2019 as "National Myasthenia Gravis Awareness
20190HR0425PN2251 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30